Funding for this research was provided by:
National Institutes of Health (F30 CA210334, R01 CA175386, R01 CA108961)
Text and Data Mining valid from 2019-07-17
Received: 22 January 2019
Accepted: 10 July 2019
First Online: 17 July 2019
Ethics approval and consent to participate
: All in vivo studies were performed with the approval of the Mayo Clinic’s Institutional Animal Care and Use Committee (IACUC).
: Not applicable.
: Matt Coffey is president and chief executive officer of Oncolytics Biotech, the maker of the reovirus used in this study.